Roswell Park Cancer Institute: Leukemia trials

The registry lists 35 Leukemia studies with Roswell Park Cancer Institute as lead sponsor. 0 are open to participants now and 13 have results posted.

Phase 1 11Phase 2 18Phase 3 2No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT02029417Phase 2Results posted
• Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic LeukemiaTerminatedNCT01649791Not applicableResults posted
• Rasburicase and Allopurinol in Treating Patients With Hematologic MalignanciesTerminatedNCT01564277Phase 2Results posted
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 2Results posted
• Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure DisordersCompletedNCT00856388Not applicableResults posted
• Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT00814164Phase 2Results posted
• High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid TumorsCompletedNCT00536601Not applicableResults posted
• Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell TransplantCompletedNCT00534118Not applicableResults posted
• Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT00096044Phase 2Results posted
• Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic LeukemiaCompletedNCT00096018Phase 1/2Results posted
• NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/DisordersCompletedNCT00053989Phase 2Results posted
• Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic CancerCompletedNCT00003816Phase 2/3Results posted
• Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003270Phase 2Results posted
• Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT04207190Phase 1
• Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene MutationWithdrawnNCT03881735Phase 2
• Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic LeukemiaWithdrawnNCT03851081Phase 1/2
• DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01834248Phase 1
• Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantWithdrawnNCT01558778Not applicable
• Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01555268Phase 1
• Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT01550185Phase 1
• Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction ChemotherapyTerminatedNCT01521936Phase 2
• Azadirachta Indica in Treating Patients With Chronic Lymphocytic LeukemiaWithdrawnNCT01251250Phase 1
• Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01246622Phase 1
• Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00093483Phase 1
• High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid TumorsCompletedNCT00060255Phase 2
• Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic DisordersCompletedNCT00055653Phase 2
• Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00054171Phase 2
• Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic AnemiaCompletedNCT00053157Not applicable
• Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous LeukemiaCompletedNCT00053144Phase 1
• Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00053131Phase 2
• Thalidomide in Treating Anemia in Patients With Myelodysplastic SyndromeCompletedNCT00030550Phase 2
• Vaccine Therapy in Preventing Flu in Children With Acute Lymphoblastic LeukemiaCompletedNCT00022035Not applicable
• Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003661Phase 2
• Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic CancerCompletedNCT00003294Phase 1
• High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00002945Phase 3